Adagene Inc. American Depositary Shares (ADAG)

Adagene initiated a Phase 2 clinical trial for muzastotug (ADG126) in combination with KEYTRUDA for microsatellite stable colorectal cancer, randomizing patients to 10 or 20 mg/kg doses with anticipated trial completion in early 2027.

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Charge Enterprises, Inc. (NA...

Here is how Boston Scientific (BSX) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.